Tyra Biosciences SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company developing FGFR-focused precision medicines. Recent 8-K reports cover operating results, clinical-program updates for TYRA-300/dabogratinib, officer and board appointments, and capital actions under a registered at-the-market offering program.
Proxy materials describe annual meeting voting matters, board structure and corporate-governance procedures. Registration-linked disclosures and material-event reports also identify TYRA common stock, equity issuance activity, and the company’s use of SEC exhibits for press releases and other official corporate records.
Tyra Biosciences, Inc. (TYRA) is reported to have a significant shareholder group led by Biotechnology Value Fund entities and Mark N. Lampert, which collectively may be deemed to beneficially own 4,215,886 shares of Tyra’s common stock, or approximately 6.1% of the outstanding shares as of September 21, 2026.
The stake is held across several affiliated funds: BVF holds 2,203,710 shares (about 3.2%), BVF2 holds 1,651,007 shares (about 2.4%), and Biotechnology Value Trading Fund OS holds 278,491 shares (less than 1%). Voting and dispositive power is shared among BVF GP, BVF2 GP, Partners OS, BVF GP Holdings, BVF Partners L.P., BVF Inc., and Mr. Lampert, with multiple entities disclaiming beneficial ownership of shares held by affiliates.
The ownership percentages are calculated using 59,676,939 shares outstanding as of July 31, 2026 plus 9,079,000 shares issued in an offering described in a prospectus supplement filed September 15, 2026; this share count is used solely as the denominator for the reported percentages.
Tyra Biosciences, Inc. (TYRA) reported that President and CEO Todd Harris acquired common stock through an equity plan. On September 15, 2026, he received 864 shares of common stock at $9.129 per share under the company’s 2021 Employee Stock Purchase Plan. Following this grant, he directly holds 1,438,495 shares of common stock, which include restricted stock units. No transactions are reported under a Rule 10b5-1 trading plan.
Tyra Biosciences, Inc. (TYRA) reported that Vice President, Finance (PAO) Yuliya Rueb acquired 2,925 shares of common stock on September 15, 2026 as a grant or award. The filing notes the shares were acquired under Tyra’s 2021 Employee Stock Purchase Plan, bringing her directly held common stock (including restricted stock units) to 11,258 shares. A prior Form 4 had overstated her beneficial ownership due to a clerical error, which this filing corrects.
Tyra Biosciences, Inc. (TYRA) reported that its Chief Financial Officer, Alan Fuhrman, acquired 951 shares of common stock on September 15, 2026 through a grant or award under the company’s 2021 Employee Stock Purchase Plan at $9.129 per share. Following this acquisition, Fuhrman directly holds 37,115 shares of common stock, which includes restricted stock units. No transactions in this filing were made under a Rule 10b5-1 trading plan.
Tyra Biosciences, Inc. (TYRA) received an updated Schedule 13D/A from RA Capital Management, L.P. and related reporting persons reflecting a sizable position capped by warrant terms. The group reports beneficial ownership of 14,130,492 shares of common stock, equal to 19.99% of the class, including common shares, stock options and Pre-Funded Warrants that are exercisable within 60 days, subject to a 19.99% ownership blocker.
The Fund purchased additional Pre-Funded Warrants on September 15, 2026, exercisable for up to 9,078,529 shares at $22.029 per warrant, for an aggregate $199,990,915.34, funded from its working capital. Each Pre-Funded Warrant has a de minimis exercise price of $0.001 per share, is immediately exercisable, does not expire, and includes a blocker preventing ownership above 19.99%, adjustable with 61 days’ notice.
Tyra Biosciences, Inc. (TYRA) had a large insider-related purchase of derivative securities reported by RA Capital–affiliated entities. They purchased 9,078,529 Pre-Funded Warrants, each exercisable for one share of common stock at an exercise price of $0.001 per share, for $22.029 per warrant in an open-market or private transaction on September 15, 2026. The warrants are exercisable immediately, have no expiration date, and include a 19.99% beneficial ownership cap on post-exercise common stock. The position is held indirectly through RA Capital Healthcare Fund LP, and the investment manager and its principals disclaim beneficial ownership except to the extent of their pecuniary interest. No Rule 10b5-1 trading plan is reported.
Tyra Biosciences, Inc. (TYRA) is reported to have a significant shareholder group led by Paradigm BioCapital. Paradigm BioCapital Advisors LP, its general partner Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. each report beneficial ownership of 3,473,453 shares of Tyra common stock, representing 5.8% of the outstanding shares. Paradigm BioCapital International Fund Ltd. separately reports 3,060,595 shares, or 5.1%. These positions are based on 59,676,939 shares of common stock outstanding as of July 31, 2026. The Fund and one or more separately managed accounts managed by Paradigm BioCapital Advisors LP directly hold the shares, and the other reporting persons may be deemed to share beneficial ownership through their roles in the advisory structure, while each disclaims ownership beyond securities directly held.
Tyra Biosciences, Inc. (TYRA) entered into an underwriting agreement for an underwritten offering of 9,079,000 shares of common stock at $22.03 per share and, for certain investors, pre-funded warrants to purchase 9,078,529 shares of common stock at $22.029 per warrant. Underwriters will purchase the common shares at $20.7082 per share and the pre-funded warrants at $20.7072 per warrant, and Tyra expects gross proceeds of approximately $400.0 million before underwriting discounts, commissions and expenses. The offering is expected to close on September 15, 2026, subject to customary closing conditions.
Each pre-funded warrant has a $0.001 exercise price per share, is immediately exercisable, and does not expire, but includes a beneficial ownership limitation generally capped at 4.99%, 9.99% or 19.99% of outstanding common stock, adjustable up to a maximum of 19.99% with 61 days’ notice. Tyra states it intends to use the net proceeds, together with existing cash, cash equivalents and marketable securities, to advance its dabogratinib “3x3” development strategy in LG-UTUC, IR NMIBC and ACH, and to support other preclinical and discovery programs, working capital and general corporate purposes.
Tyra Biosciences, Inc. (TYRA) is conducting a primary offering of 9,079,000 shares of common stock and pre-funded warrants to purchase 9,078,529 shares, under its shelf registration. The common stock is priced at $22.03 per share and the pre-funded warrants at $22.029 each, with a $0.001 exercise price per underlying share.
Gross proceeds are approximately $400.0 million, with net proceeds to Tyra of about $373.9 million after underwriting discounts, commissions and expenses. Tyra plans to use the proceeds, together with existing cash and investments, to advance its “dabogratinib 3x3” development strategy in FGFR-related indications, support preclinical and discovery programs, and for working capital and general corporate purposes.
The offering creates immediate dilution: net tangible book value per share increases from $5.93 to $10.58, implying $11.45 per-share dilution to new investors. Pre-funded warrants are exercisable at any time, subject to a 4.99%–19.99% beneficial ownership cap, will not be listed, and are expected to have limited liquidity.
Tyra Biosciences, Inc. (TYRA) has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, allowing it to offer and sell, from time to time after effectiveness, common stock, preferred stock, debt securities, warrants and units in one or more future offerings. Specific terms, amounts and prices for each issuance will be detailed in accompanying prospectus supplements.
Tyra is a clinical-stage biotechnology company focused on precision medicines targeting FGFR biology, built on its in-house SNÅP drug-design platform. Its lead oral candidate, dabogratinib, is in development for multiple urothelial and bladder cancer indications and achondroplasia, alongside additional FGFR-focused programs TYRA-430 and TYRA-200 in liver and cholangiocarcinoma studies.
As of June 30, 2026, Tyra’s authorized capital stock consisted of 500,000,000 shares of common stock and 50,000,000 shares of preferred stock. Its common stock trades on the Nasdaq Global Select Market under the symbol TYRA, with a last reported sale price of $22.03 per share on September 11, 2026. The filing also describes anti-takeover provisions under Delaware law and the company’s charter and bylaws.